Horizon數位前沿主動型ETF YNOT 深 滬
等待開盤 08-10 09:30:00 美东时间
32.8017
+0.501
+1.55%
華盛通- 最 高32.99
- 今 開32.99
- 成交量 1.42万股
- 最 低 32.37
- 昨 收 32.3003
- 總市值 1.91亿
- 52周最高 35.02
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 25.1901
- 委 比 17.65%
- 總股本 582.00万
- 歷史最高 35.02
- 量 比 0.05
- 振 幅 1.92%
- 歷史最低 25.08
- 每 手 1
- 風險率 2.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gilead's Trodelvy gains new breast cancer indications
The US FDA has approved Gilead Sciences' (GILD) Trodelvy (sacituzumab govitecan) as a first-line treatment as monotherapy and in combination with Merck's (MRK) Keytruda (pembrolizumab) for triple-nega...
06-25 04:37
Moderna snaps after six-session winning streak
Moderna (MRNA) snapped a six-session winning streak on Monday, with shares falling 6.10% to $60.06 in afternoon trading. Despite the decline, the stock has been one of the market's standout performers...
06-23 02:05
Moderna gains unanimous FDA panel endorsement of flu vaccine
A US FDA advisory panel unanimously agreed that the benefits of Moderna's (MRNA) mRNA seasonal flu vaccine, mRNA-1010, outweigh the risks in individuals 50-75 years old. The agency's Vaccines and Rela...
06-19 05:00
Moderna eyes German production sites amid BioNTech plant closures - report
U.S. vaccine maker Moderna (MRNA) is exploring investments in manufacturing facilities in Germany and is particularly interested in acquiring sites that rival BioNTech (BNTX) plans to shut down as par...
06-17 15:19
Moderna hires commercial chief ahead of multiple product launches
Moderna (MRNA) on Tuesday said that Ester Banque, a former senior executive at Zoetis (ZTS) and Bristol Myers (BMY), will join the company as chief commercial officer as part of organizational changes...
06-16 20:57
默沙东(MRK)股票6月15日盘中下跌3.13%：真相来了
• CMS拟议的药品价格谈判影响了默克未来的营收。 • 肿瘤学试验中的研发管线受挫，引发了市场对增长前景的担忧。 • 除息日因素也导致了股价的下跌。
06-15 18:16
Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's
06-09 04:31
